Forward-Looking StatementsThis press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Title: Sorrento Therapeutics COVID-19 Pipeline Update, R&D Discussion and Management Q&A. Date of call: 10/13/2020 Time of call: 16:30 Eastern Time Expected Duration: 60 minutes + … Mark Brunswick, SVP and Head of Regulatory and QualityDr. Title: Sorrento Therapeutics COVID-19 Pipeline Update, R&D Discussion and Management Q&A, Expected Duration: 60 minutes + questions (analysts and general public), For registered analysts and pre-certified participants, For other participants (webcast, with ability to submit questions during the session): https://edge.media-server.com/mmc/p/tun863t9, Management participants will include: Dr. Henry Ji, Chairman and CEO, Dr. Mark Brunswick, SVP and Head of Regulatory and Quality, Dr. Robert Allen, SVP, Antiviral and Oncolytic Immunotherapy Development, Dr. Alexis Nahama, SVP of Corporate Development, R&D Day Agenda: Strategic Outlook (Dr. Henry Ji), Therapeutic Pipeline - Clinical Stage (Management), Therapeutic Pipeline - IND enabling Stage (Management), STI-2099 (encoded plasmid DNA expressing STI-2020), Neutralizing antibody cocktail (COVI-SHIELD), STI-4398 (COVIDTRAP: ACE2 receptor decoy protein), STI-3333 (T-VIVA-19: protein-based vaccine), COVI-TRACE: HP-LAMP Molecular Detection Test. The webcast will be available on the Sorrento Therapeutics’ website for 30 days at www.sorrentotherapeutics.com. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento’s and its subsidiaries’, affiliates’ and partners’ technologies and prospects and collaborations, including, but not limited to clinical development risks, including risks in the progress, timing, cost, and results of clinical trials and product development programs; risk of difficulties or delays in obtaining regulatory approvals; risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval; risks that prior test, study and trial results may not be replicated in future studies and trials; risks of manufacturing and supplying drug product; risks related to leveraging the expertise of its employees, subsidiaries, affiliates and partners to assist the company in the execution of its therapeutic and diagnostic product candidates’ strategies; risks related to the global impact of COVID-19; and other risks that are described in Sorrento’s most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento’s Annual Report on Form 10-K for the year ended December 31, 2019, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Dr. Orelli is a Senior Biotech Specialist. The main purpose of the early-stage study is twofold: Assess the safety of the treatment and measure its risk/benefit ratio. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release except as required by law. Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVIDTRAP, ACE-MAB, COVI-MAB, COVI-GUARD, COVI-SHIELD, COVI-AMG and T-VIVA-19 and diagnostic test solutions, including COVI-TRACK, COVI-STIX and COVI-TRACE. The Food and Drug Administration (FDA) authorized the start of a 20-patient phase 1 clinical trial in July, but the study hasn't started recruiting patients, according to ClinicalTrials.gov. Alexis Nahama, SVP of Corporate Development, • Therapeutic Pipeline – Clinical Stage (Management), • Therapeutic Pipeline – IND enabling Stage (Management). He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007. Sorrento Therapeutics (SRNE -14.7%) is under pressure, albeit on below-average volume, following yesterday's corporate overview by chief Henry Ji, Ph.D. Forward-looking statements include statements regarding Sorrento’s pipeline and plans with respect to its strategic outlook and clinical and pre-clinical COVID-19 programs, its COVID-19 therapeutic and diagnostic product candidates and pipeline, and its proprietary technology platforms. Beware of Investing in These 3 Small-Cap Coronavirus Stocks, Copyright, Trademark and Patent Information. The biotech licensed an adipose-derived mesenchymal stem cell (MSC) treatment from Personalized Stem Cells for patients with acute respiratory distress syndrome associated with COVID-19. Financial terms of the deal weren't disclosed. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies ('G-MAB library'), clinical stage immuno-cellular therapies ('CAR-T', 'DAR-T'), antibody-drug conjugates ('ADCs'), and clinical stage oncolytic virus ('Seprehvir', 'Seprehvec'). Sorrento Announces That Intranasal Administration of COVI-AMG™ Neutrali.. Chairman, President & Chief Executive Officer, VP-Pharmacovigilance & Clinical Operations. Right now, Sorrento is awaiting an Emergency Use Authorization (EUA) from the FDA for its COVID-19 diagnostic and antibody tests. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies ("G-MAB™ library"), clinical stage immuno-cellular therapies ("CAR-T", "DAR-T"), antibody-drug conjugates ("ADCs"), and clinical stage oncolytic virus ("Seprehvir®", “Seprehvec™”). The MSC treatment was derived from fat cells, but the cells have the ability to turn into other types of tissue. Stock Advisor launched in February of 2002. © 2020 Sorrento Therapeutics, Inc. All Rights Reserved. ZTlido was approved by the FDA on February 28, 2018. The MSC treatment joins Sorrento's other COVID-19 treatments, including abivertinib, salicyn-30, STI-1499 and STI-2020. Conference ID: 2066037. Abivertinib was developed as a cancer treatment, but Sorrento hopes it could also help patients with COVID-19 by dampening the overactive immune system, which can cause problems in patients with COVID-19. Is Sorrento Therapeutics a Ticking Time Bomb for Investors? This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release except as required by law. Robert Allen, SVP, Antiviral and Oncolytic Immunotherapy DevelopmentDr. Sorrento Therapeutics (NASDAQ:SRNE) has added another arrow to its COVID-19 quiver. A vulnerable pipeline. Mike Royal, Chief Medical OfficerDr. Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin ('RTX'), and ZTlido (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. Sorrento Therapeutics Adds Another COVID-19 Treatment to Its Pipeline The company's pipeline is large. Its list of FDA-authorized drugs is nonexistent. Sorrento will take over the execution of the phase 1 study from Personalized Stem Cells. SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today released details about its upcoming COVID-19 Pipeline Update call and webcast on October 13 th, 2020.. Market data powered by FactSet and Web Financial Group. Returns as of 11/03/2020. Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Therapeutics’ Large Phase 2 Clinical Trial of Abivertinib in Mild, Moderate and Severe COVID-19 Patients Oct 12, 2020 Sorrento Adds Mesenchymal Stem Cell Program (MSC) That Has Been Cleared for a Phase 1 Trial by the FDA to the Pipeline of COVID-19 Focused Rescue Therapies Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVIDTRAP™, ACE-MAB™, COVI-MAB™, COVI-GUARD™, COVI-SHIELD™, COVI-AMG™ and T-VIVA-19™; and diagnostic test solutions, including COVI-TRACK™, COVI-STIX™ and COVI-TRACE™. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life.